The Association of Procalcitonin and C-Reactive Protein with Bacterial Infections Acquired during Intensive Care Unit Stay in COVID-19 Critically Ill Patients.
C-reactive protein
COVID-19
intensive care unit
procalcitonin
secondary infections
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
12 Oct 2023
12 Oct 2023
Historique:
received:
03
09
2023
revised:
22
09
2023
accepted:
09
10
2023
medline:
27
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
In COVID-19 patients, procalcitonin (PCT) and C-reactive protein (CRP) performance in identifying bacterial infections remains unclear. Our study aimed to evaluate the association of PCT and CRP with secondary infections acquired during ICU stay in critically ill COVID-19 patients. This observational study included adult patients admitted to three COVID-19 intensive care units (ICUs) from February 2020 to May 2022 with respiratory failure caused by SARS-CoV-2 infection and ICU stay ≥ 11 days. The values of PCT and CRP collected on the day of infection diagnosis were compared to those collected on day 11 after ICU admission, the median time for infection occurrence, in patients without secondary infection. The receiver operating characteristic curve (ROC) and multivariate logistic model were used to assess PCT and CRP association with secondary infections. Two hundred and seventy-nine patients were included, of whom 169 (60.6%) developed secondary infection after ICU admission. The PCT and CRP values observed on the day of the infection diagnosis were larger (
Identifiants
pubmed: 37887237
pii: antibiotics12101536
doi: 10.3390/antibiotics12101536
pmc: PMC10604665
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Thorac Oncol. 2010 Sep;5(9):1315-6
pubmed: 20736804
J Med Virol. 2021 Mar;93(3):1832-1836
pubmed: 33241872
Crit Care. 2021 Aug 5;25(1):281
pubmed: 34353339
Clin Infect Dis. 2009 Dec 1;49(11):1770-1; author reply 1771-2
pubmed: 19891568
Intensive Care Med. 2023 Aug;49(8):934-945
pubmed: 37507573
Antibiotics (Basel). 2023 Apr 05;12(4):
pubmed: 37107071
Clin Microbiol Infect. 2021 Mar;27(3):389-395
pubmed: 33359375
J Infect. 2022 Oct;85(4):374-381
pubmed: 35781017
Antibiotics (Basel). 2023 Jan 12;12(1):
pubmed: 36671362
J Crit Care. 2017 Oct;41:91-97
pubmed: 28502892
Am J Respir Crit Care Med. 2005 Feb 1;171(3):242-8
pubmed: 15557131
Life (Basel). 2021 Mar 20;11(3):
pubmed: 33804790
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
Infection. 2021 Oct;49(5):935-943
pubmed: 34021897
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Virol J. 2023 May 8;20(1):92
pubmed: 37158904
BMJ Evid Based Med. 2021 Jun;26(3):107-108
pubmed: 32934000
Intensive Care Med. 2012 Jun;38(6):940-9
pubmed: 22538461
J Intensive Care Med. 2022 Nov;37(11):1486-1492
pubmed: 35711161
Cureus. 2022 Sep 7;14(9):e28898
pubmed: 36237753
Crit Care. 2020 Jun 1;24(1):281
pubmed: 32487263
Intensive Care Med. 2021 Nov;47(11):1181-1247
pubmed: 34599691
Antibiotics (Basel). 2021 Nov 22;10(11):
pubmed: 34827363
Cochrane Database Syst Rev. 2012 Sep 12;(9):CD007498
pubmed: 22972110